Lipid profile in obese and non-obese women with polycystic ovary syndrome treated with metformin;Perfil lipidico en mujeres obesas y no obesas con sindrome de ovarios poliquisticos tratadas con metformina

Endocrinologia y Nutricion

Volumn 57, Issue 6, 2010, Pages 262-267

  Quintero Castillo, Daimarys ^a   Luz Araujo, Hedy ^a   Guerra Velázquez, Mery ^a   Reyna Villasmil, Eduardo ^a   Bolivar, Joel Santos ^a   Torres Cepeda, Duly ^a   Mejia Montilla, Jorly ^a   Reyna Villasmil, Nadia ^a  

^a HOSPITAL CENTRAL DR URQUINAONA   (Venezuela)

Author keywords

Lipids; Metformin; Obesity; Polycystic ovary syndrome

Indexed keywords

CHOLESTEROL; LIPOPROTEIN; METFORMIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD; COMPARATIVE STUDY; FEMALE; HUMAN; METABOLISM; OBESITY; OVARY POLYCYSTIC DISEASE;

CHOLESTEROL; FEMALE; HUMANS; LIPOPROTEINS; METFORMIN; OBESITY; POLYCYSTIC OVARY SYNDROME; TRIGLYCERIDES; YOUNG ADULT;

EID: 79952202059     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2010.04.001     Document Type: Article

References (29)

1. Tang T, Glanville J, Hayden C, White D, Barth J, Balen A. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Hum Reprod. 2006;21:80-9. (Pubitemid 41794294)
2. Sanchez L, Azziz R. Sindrome de ovario poliquistico, evaluación, diagnostico, tratamiento y pronostico. Rev Obstet Ginecol Venez. 2000;60:47-57.
3. Birdsall M, Farquhar C, White H. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med. 1997;126:32-5. (Pubitemid 27021216)
4. Cheang K, Nestler J, Futterweit W. Risk of cardiovascular events in mothers of women with polycystic ovary syndrome. Endocr Pract. 2008;14:1084-94.
5. Dejager S, Pichard C, Giral P, Bruckert E, Federspield M, Beucler I, et al. Smaller LDL particle size in women with polycystic ovary syndrome compared to controls. Clin Endocrinol (Oxf). 2001;54:455-62. (Pubitemid 34204181)
6. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Tapanainen J. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum Reprod. 2000;15:1266-74. (Pubitemid 30335948)
7. Pardo R. Sindrome de ovarios poliquisticos: una disfuncion metabolica de alto riesgo cardiovascular. Rev Obstet Ginecol Venez. 1999;59:117-36.
8. Reyna E, Torres M, Reyna N, Mejia J. Homocisteina plasmática en pacientes con sindrome de ovarios poliquisticos. Rev Obstet Ginecol Venez. 2003;63:87-93.
9. Glueck C, Morrison J, Wang P. Insulin resistance, obesity, hypofibrinolysis, hyperandrogenism, and coronary heart disease risk factors in 25 pre-perimenarchal girls age < or=14years, 13 with precocious puberty, 23 with a first-degree relative with polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2008;21:973-84.
10. Paoli De Valeri M, Mendoza S, Velazquez E. Terapia esteroidea en el sindrome de ovarios poliquisticos: efectos sobre lipidos, insulina y hormonas sexuales. Rev Obstet Ginecol Venez. 1993;53:95-101. (Pubitemid 23240491)
11. Alexander C, Tangchitnob E, Lepor N. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol. 2009;2:232-9.
12. Yilmaz M, Karakoc A, Törüner F, Cakir N, Tiras B, Ayvaz G, et al. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecol Endocrinol. 2005;21:154-60. (Pubitemid 41597556)
13. Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome-a randomised, doubleblind, placebo-controlled trial. BJOG. 2006;113:817-24. (Pubitemid 43961744)
14. Cibula D, Sindelka G, Hill M, Fanta M, Skrha J, Zivny J. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing lowandrogenic progestin. Hum Reprod. 2002;17:76-82. (Pubitemid 34130264)
15. Wu X, Zhou S, Liu J, Pöllänen P, Sallinen K, Mäkinen M, et al. Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. Fertil Steril. 2003;80:954-65. (Pubitemid 37230033)
16. Chaudhury K, Chaudhury S, Chowdhury S. Does metformin augment the ovulation inducing effects of clomiphene in nonobese women with polycystic ovary syndrome? J Indian Med Assoc. 2008;106:643-8.
17. Li X, Lin J. Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome. Zhonghua Yi Xue Za Zhi. 2005;85:3266-71. (Pubitemid 43173658)
18. Teede H, Meyer C, Norman R. Insulin-sensitisers in the treatment of polycystic ovary syndrome. Expert Opin Pharmacother. 2005;6:2419-27. (Pubitemid 41701044)
19. Zain M, Jamaluddin R, Ibrahim A, Norman R. Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril. 2009;91:514-21.
20. Kriplani A, Agarwal N. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. J Reprod Med. 2004;49:361-7. (Pubitemid 38668278)
21. Creanga A, Bradley H, McCormick C, Witkop C. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol. 2008;111:959-68. (Pubitemid 351482630)
22. Aruna J, Mittal S, Kumar S, Misra R, Dadhwal V, Vimala N. Metformin therapy in women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2004;87:237-41. (Pubitemid 39535085)
23. Lee H, Oh J, Sung Y, Chung H, Cho W. The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome. Endocrine. 2009;36:326-32.
24. Costello M, Shrestha B, Eden J, Sjoblom P, Johnson N. Insulinsensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007:CD005552.
25. Schultes B, Oltmanns K, Kern W, Fehm H, Born J, Peters A. Modulation of hunger by plasma glucose and metformin. J Clin Endocrinol Metab. 2003;88:1133-41. (Pubitemid 36337767)
26. Velazquez E, Mendoza S, Hamer T, Sosa F, Glueck C. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43:647-54. (Pubitemid 24145474)
27. La Marca A, Egbe T, Morgante G, Paglia T, Cianci A, De Leo V. Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod. 2000;15:21-3. (Pubitemid 30035093)
28. Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol. 2003;17:51-6. (Pubitemid 36349882)
29. Glueck C, Fontaine R, Wang P, Subbiah M, Weber K, Illig E, et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism. 2001;50:856-61. (Pubitemid 32700469)